메뉴 건너뛰기




Volumn 21, Issue 3, 2014, Pages 1024-1030

Src family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FOCAL ADHESION KINASE; MELPHALAN; PROTEIN TYROSINE KINASE;

EID: 84896731491     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3387-6     Document Type: Article
Times cited : (4)

References (45)
  • 1
    • 80052483131 scopus 로고    scopus 로고
    • Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors
    • 1:CAS:528:DC%2BC3MXhtFSmtLnP 21670084 10.1158/1078-0432.CCR-10-2616
    • Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546-52.
    • (2011) Clin Cancer Res , vol.17 , Issue.17 , pp. 5546-5552
    • Montero, J.C.1    Seoane, S.2    Ocana, A.3    Pandiella, A.4
  • 2
    • 70349758510 scopus 로고    scopus 로고
    • Src kinases as therapeutic targets for cancer
    • 19787002 10.1038/nrclinonc.2009.129
    • Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587-95.
    • (2009) Nat Rev Clin Oncol , vol.6 , Issue.10 , pp. 587-595
    • Kim, L.C.1    Song, L.2    Haura, E.B.3
  • 3
    • 2942618768 scopus 로고    scopus 로고
    • A renaissance for SRC
    • 1:CAS:528:DC%2BD2cXksVaisbo%3D 15170449 10.1038/nrc1366
    • Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470-80.
    • (2004) Nat Rev Cancer , vol.4 , Issue.6 , pp. 470-480
    • Yeatman, T.J.1
  • 4
    • 0038386613 scopus 로고    scopus 로고
    • Src family kinases in tumor progression and metastasis
    • 1:CAS:528:DC%2BD3sXjslyiu74%3D 12884910 10.1023/A:1023772912750
    • Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22(4):337-58.
    • (2003) Cancer Metastasis Rev , vol.22 , Issue.4 , pp. 337-358
    • Summy, J.M.1    Gallick, G.E.2
  • 5
    • 33847728182 scopus 로고    scopus 로고
    • A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
    • 1:CAS:528:DC%2BD2sXhvVWqsbs%3D 17308097 10.1158/0008-5472.CAN-06-2027
    • Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007;67(4):1580-8.
    • (2007) Cancer Res , vol.67 , Issue.4 , pp. 1580-1588
    • Jallal, H.1    Valentino, M.L.2    Chen, G.3    Boschelli, F.4    Ali, S.5    Rabbani, S.A.6
  • 6
    • 33846261886 scopus 로고    scopus 로고
    • The Src signaling pathway: A potential target in melanoma and other malignancies
    • 1:CAS:528:DC%2BD28Xht1yisL7M 17150037 10.1517/14728222.11.1.91
    • Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007;11(1):91-100.
    • (2007) Expert Opin Ther Targets , vol.11 , Issue.1 , pp. 91-100
    • Homsi, J.1    Cubitt, C.2    Daud, A.3
  • 7
    • 1642551021 scopus 로고    scopus 로고
    • Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
    • 1:CAS:528:DC%2BD2cXivFSqsrY%3D 15073106 10.1158/1078-0432.CCR-1183-3
    • Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10(7):2307-18.
    • (2004) Clin Cancer Res , vol.10 , Issue.7 , pp. 2307-2318
    • Duxbury, M.S.1    Ito, H.2    Zinner, M.J.3    Ashley, S.W.4    Whang, E.E.5
  • 8
    • 0037784223 scopus 로고    scopus 로고
    • Pp60c-src activation in lung adenocarcinoma
    • 1:CAS:528:DC%2BD3sXkvVWjsrw%3D 12826049 10.1016/S0959-8049(03)00276-4
    • Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer. 2003;39(10):1447-55.
    • (2003) Eur J Cancer , vol.39 , Issue.10 , pp. 1447-1455
    • Masaki, T.1    Igarashi, K.2    Tokuda, M.3
  • 9
    • 0037150728 scopus 로고    scopus 로고
    • Src in cancer: Deregulation and consequences for cell behaviour
    • 1:CAS:528:DC%2BD38XjvVeitLs%3D 12020799
    • Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002;1602(2):114-30.
    • (2002) Biochim Biophys Acta , vol.1602 , Issue.2 , pp. 114-130
    • Frame, M.C.1
  • 10
    • 0037080135 scopus 로고    scopus 로고
    • Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
    • 11900220 10.1002/cncr.10221
    • Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94(2):344-51.
    • (2002) Cancer , vol.94 , Issue.2 , pp. 344-351
    • Aligayer, H.1    Boyd, D.D.2    Heiss, M.M.3    Abdalla, E.K.4    Curley, S.A.5    Gallick, G.E.6
  • 11
    • 19944428353 scopus 로고    scopus 로고
    • Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
    • 1:CAS:528:DC%2BD2cXhtVKrsrnI 15615512 10.1021/jm049486a
    • Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-61.
    • (2004) J Med Chem , vol.47 , Issue.27 , pp. 6658-6661
    • Lombardo, L.J.1    Lee, F.Y.2    Chen, P.3
  • 12
    • 79955500900 scopus 로고    scopus 로고
    • A phase 2 trial of dasatinib in advanced melanoma
    • 1:CAS:528:DC%2BC3MXltFyms7g%3D 3116034 21523734 10.1002/cncr.25766
    • Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202-8.
    • (2011) Cancer , vol.117 , Issue.10 , pp. 2202-2208
    • Kluger, H.M.1    Dudek, A.Z.2    McCann, C.3
  • 13
    • 33749021085 scopus 로고    scopus 로고
    • Somatic activation of KIT in distinct subtypes of melanoma
    • 1:CAS:528:DC%2BD28XhtVGju7bM 16908931 10.1200/JCO.2006.06.2984
    • Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-6.
    • (2006) J Clin Oncol , vol.24 , Issue.26 , pp. 4340-4346
    • Curtin, J.A.1    Busam, K.2    Pinkel, D.3    Bastian, B.C.4
  • 14
    • 50249141632 scopus 로고    scopus 로고
    • Phase II trial of imatinib mesylate in patients with metastatic melanoma
    • 1:CAS:528:DC%2BD1cXhtVGgtb%2FK 2528157 18728664 10.1038/sj.bjc.6604482
    • Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734-40.
    • (2008) Br J Cancer , vol.99 , Issue.5 , pp. 734-740
    • Kim, K.B.1    Eton, O.2    Davis, D.W.3
  • 15
    • 33646268037 scopus 로고    scopus 로고
    • Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy
    • 1:CAS:528:DC%2BD28XkvFGhs7g%3D 16565971 10.1002/cncr.21834
    • Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005-11.
    • (2006) Cancer , vol.106 , Issue.9 , pp. 2005-2011
    • Wyman, K.1    Atkins, M.B.2    Prieto, V.3
  • 16
    • 21044460131 scopus 로고    scopus 로고
    • Lack of clinical efficacy of imatinib in metastatic melanoma
    • 1:CAS:528:DC%2BD2MXjsVSjtro%3D 2362005 15846297 10.1038/sj.bjc.6602529
    • Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398-405.
    • (2005) Br J Cancer , vol.92 , Issue.8 , pp. 1398-1405
    • Ugurel, S.1    Hildenbrand, R.2    Zimpfer, A.3
  • 17
    • 79960708519 scopus 로고    scopus 로고
    • Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification
    • 1:CAS:528:DC%2BC3MXhtVOqsLnJ 21690468 10.1200/JCO.2010.33.9275
    • Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-9.
    • (2011) J Clin Oncol , vol.29 , Issue.21 , pp. 2904-2909
    • Guo, J.1    Si, L.2    Kong, Y.3
  • 18
    • 79958066836 scopus 로고    scopus 로고
    • KIT as a therapeutic target in metastatic melanoma
    • 1:CAS:528:DC%2BC3MXntlOnsrY%3D 21642685 10.1001/jama.2011.746
    • Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
    • (2011) JAMA , vol.305 , Issue.22 , pp. 2327-2334
    • Carvajal, R.D.1    Antonescu, C.R.2    Wolchok, J.D.3
  • 19
    • 33748340618 scopus 로고    scopus 로고
    • A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity
    • 16791448 10.1245/ASO.2006.05.003
    • Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13(8):1123-9.
    • (2006) Ann Surg Oncol , vol.13 , Issue.8 , pp. 1123-1129
    • Brady, M.S.1    Brown, K.2    Patel, A.3    Fisher, C.4    Marx, W.5
  • 20
    • 3843113670 scopus 로고    scopus 로고
    • Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?
    • 1:CAS:528:DC%2BD2cXmt1OitL0%3D 15288283 10.1016/j.ejca.2004.04.030
    • Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40(12):1825-36.
    • (2004) Eur J Cancer , vol.40 , Issue.12 , pp. 1825-1836
    • Eggermont, A.M.1    Kirkwood, J.M.2
  • 21
    • 0036210893 scopus 로고    scopus 로고
    • Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma
    • 11888868
    • Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127-36.
    • (2002) Ann Surg Oncol , vol.9 , Issue.2 , pp. 127-136
    • Lindner, P.1    Doubrovsky, A.2    Kam, P.C.3    Thompson, J.F.4
  • 22
    • 77950827393 scopus 로고    scopus 로고
    • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma
    • 1:CAS:528:DC%2BC3cXktlCqtro%3D 20371714 10.1158/1535-7163.MCT-09-0764
    • Augustine CK, Jung SH, Sohn I, et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther. 2010;9(4):779-90.
    • (2010) Mol Cancer Ther , vol.9 , Issue.4 , pp. 779-790
    • Augustine, C.K.1    Jung, S.H.2    Sohn, I.3
  • 23
    • 77954572289 scopus 로고    scopus 로고
    • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
    • 1:CAS:528:DC%2BC3cXhtFertbfM 20571072 10.1158/1535-7163.MCT-10-0073
    • Augustine CK, Toshimitsu H, Jung SH, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther. 2010;9(7):2090-101.
    • (2010) Mol Cancer Ther , vol.9 , Issue.7 , pp. 2090-2101
    • Augustine, C.K.1    Toshimitsu, H.2    Jung, S.H.3
  • 24
    • 77954951941 scopus 로고    scopus 로고
    • Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
    • 20182810 10.1245/s10434-010-0971-x
    • Toshimitsu H, Yoshimoto Y, Augustine CK, et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol. 2010;17(8):2247-54.
    • (2010) Ann Surg Oncol , vol.17 , Issue.8 , pp. 2247-2254
    • Toshimitsu, H.1    Yoshimoto, Y.2    Augustine, C.K.3
  • 25
    • 34250740979 scopus 로고    scopus 로고
    • Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents
    • 1:CAS:528:DC%2BD2sXotFalt7Y%3D 17483437 10.1158/1535-7163.MCT-06-0718
    • Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6(5):1492-500.
    • (2007) Mol Cancer Ther , vol.6 , Issue.5 , pp. 1492-1500
    • Yoshimoto, Y.1    Augustine, C.K.2    Yoo, J.S.3
  • 26
    • 33645474059 scopus 로고    scopus 로고
    • Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
    • 1:CAS:528:DC%2BD28Xitl2lu7s%3D 16546988 10.1158/1535-7163.MCT-05-0098
    • Ueno T, Ko SH, Grubbs E, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther. 2006;5(3):732-8.
    • (2006) Mol Cancer Ther , vol.5 , Issue.3 , pp. 732-738
    • Ueno, T.1    Ko, S.H.2    Grubbs, E.3
  • 27
    • 68849093078 scopus 로고    scopus 로고
    • Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
    • 1:CAS:528:DC%2BD1MXpvFCnur8%3D 3346953 19671763 10.1158/1535-7163.MCT-09- 0459
    • Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009;8(8):2079-85.
    • (2009) Mol Cancer Ther , vol.8 , Issue.8 , pp. 2079-2085
    • Woodman, S.E.1    Trent, J.C.2    Stemke-Hale, K.3
  • 28
    • 4444338326 scopus 로고    scopus 로고
    • SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling
    • 1:CAS:528:DC%2BD2cXnslCrsbw%3D 515031 15340073 10.1128/MCB.24.18.8113- 8133.2004
    • Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO. SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 2004;24(18):8113-33.
    • (2004) Mol Cell Biol , vol.24 , Issue.18 , pp. 8113-8133
    • Westhoff, M.A.1    Serrels, B.2    Fincham, V.J.3    Frame, M.C.4    Carragher, N.O.5
  • 29
    • 8544245666 scopus 로고    scopus 로고
    • Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma
    • 1:CAS:528:DC%2BD2cXpsl2hsrs%3D 15546565 10.1016/j.amjsurg.2004.07.014
    • Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188(5):532-7.
    • (2004) Am J Surg , vol.188 , Issue.5 , pp. 532-537
    • Ueno, T.1    Ko, S.H.2    Grubbs, E.3    Pruitt, S.K.4    Friedman, H.S.5    Tyler, D.S.6
  • 30
    • 7944236785 scopus 로고    scopus 로고
    • Src family kinases, key regulators of signal transduction
    • 1:CAS:528:DC%2BD2cXosFylur8%3D 15489908 10.1038/sj.onc.1208160
    • Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906-9.
    • (2004) Oncogene , vol.23 , Issue.48 , pp. 7906-7909
    • Parsons, S.J.1    Parsons, J.T.2
  • 31
    • 84855345509 scopus 로고    scopus 로고
    • Phase i clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
    • 3251861 22127285 10.1038/bjc.2011.514
    • Algazi AP, Weber JS, Andrews SC, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2011;106:85-91.
    • (2011) Br J Cancer , vol.106 , pp. 85-91
    • Algazi, A.P.1    Weber, J.S.2    Andrews, S.C.3
  • 32
    • 77954216079 scopus 로고    scopus 로고
    • Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
    • 1:CAS:528:DC%2BC3cXosV2isrc%3D 20457136 10.1016/j.bcp.2010.04.032
    • Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568-74.
    • (2010) Biochem Pharmacol , vol.80 , Issue.5 , pp. 568-574
    • Woodman, S.E.1    Davies, M.A.2
  • 33
    • 54349085882 scopus 로고    scopus 로고
    • Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
    • 2569026 18823558 10.1186/1479-5876-6-53
    • Eustace AJ, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 2008;6:53.
    • (2008) J Transl Med , vol.6 , pp. 53
    • Eustace, A.J.1    Crown, J.2    Clynes, M.3    O'Donovan, N.4
  • 34
    • 67849128649 scopus 로고    scopus 로고
    • Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
    • 1:CAS:528:DC%2BD1MXlslGis7k%3D 19434004 10.1097/CMR.0b013e328304974c
    • Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009;19(3):167-75.
    • (2009) Melanoma Res , vol.19 , Issue.3 , pp. 167-175
    • Homsi, J.1    Cubitt, C.L.2    Zhang, S.3
  • 35
    • 84862561507 scopus 로고    scopus 로고
    • Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma
    • 1:CAS:528:DC%2BC38Xos1Olurk%3D 3618183 22496203 10.1158/1078-0432.CCR-11- 3000
    • Turley RS, Fontanella AN, Padussis JC, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012;18(12):3328-39.
    • (2012) Clin Cancer Res , vol.18 , Issue.12 , pp. 3328-3339
    • Turley, R.S.1    Fontanella, A.N.2    Padussis, J.C.3
  • 36
    • 0242333907 scopus 로고    scopus 로고
    • Inactivation of Src family kinases inhibits angiogenesis in vivo: Implications for a mechanism involving organization of the actin cytoskeleton
    • 1:CAS:528:DC%2BD3sXos1Citrk%3D 14597409 10.1016/S0014-4827(03)00374-4
    • Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res. 2003;291(1):70-82.
    • (2003) Exp Cell Res , vol.291 , Issue.1 , pp. 70-82
    • Kilarski, W.W.1    Jura, N.2    Gerwins, P.3
  • 37
    • 37049036163 scopus 로고    scopus 로고
    • Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability
    • 1:CAS:528:DC%2BD2sXhsVeis7%2FF 2096609 17928406 10.1091/mbc.E07-01-0004
    • Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell. 2007;18(12):5014-23.
    • (2007) Mol Biol Cell , vol.18 , Issue.12 , pp. 5014-5023
    • Petreaca, M.L.1    Yao, M.2    Liu, Y.3    Defea, K.4    Martins-Green, M.5
  • 39
    • 42949128595 scopus 로고    scopus 로고
    • Major response to imatinib mesylate in KIT-mutated melanoma
    • 1:CAS:528:DC%2BD1cXlvFaqs7Y%3D 18421059 10.1200/JCO.2007.14.0707
    • Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26(12):2046-51.
    • (2008) J Clin Oncol , vol.26 , Issue.12 , pp. 2046-2051
    • Hodi, F.S.1    Friedlander, P.2    Corless, C.L.3
  • 40
    • 0032483575 scopus 로고    scopus 로고
    • A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth
    • 1:CAS:528:DyaK1cXmtVWksr0%3D 9741627 10.1016/S0092-8674(00)81604-9
    • Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998;94(5):625-34.
    • (1998) Cell , vol.94 , Issue.5 , pp. 625-634
    • Wary, K.K.1    Mariotti, A.2    Zurzolo, C.3    Giancotti, F.G.4
  • 41
    • 79952598575 scopus 로고    scopus 로고
    • In vitro studies of dasatinib, its targets and predictors of sensitivity
    • 21320292 10.1111/j.1755-148X.2011.00835.x
    • Jilaveanu LB, Zito CR, Aziz SA, et al. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res. 2011;24(2):386-9.
    • (2011) Pigment Cell Melanoma Res , vol.24 , Issue.2 , pp. 386-389
    • Jilaveanu, L.B.1    Zito, C.R.2    Aziz, S.A.3
  • 42
    • 48149092966 scopus 로고    scopus 로고
    • Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
    • 18528730 10.1245/s10434-008-9988-9
    • Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195-205.
    • (2008) Ann Surg Oncol , vol.15 , Issue.8 , pp. 2195-2205
    • Beasley, G.M.1    Petersen, R.P.2    Yoo, J.3
  • 43
    • 45549085493 scopus 로고    scopus 로고
    • Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment
    • 1:CAS:528:DC%2BD1cXlvVOitbk%3D 18483261 10.1158/0008-5472.CAN-07-5949
    • Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008;68(10):3777-84.
    • (2008) Cancer Res , vol.68 , Issue.10 , pp. 3777-3784
    • Augustine, C.K.1    Yoshimoto, Y.2    Gupta, M.3
  • 44
    • 0036447366 scopus 로고    scopus 로고
    • Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
    • 1:CAS:528:DC%2BD38XhtFCltbs%3D 11846617 10.1006/phrs.2001.0935
    • Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res. 2002;45(2):73-85.
    • (2002) Pharmacol Res , vol.45 , Issue.2 , pp. 73-85
    • Tentori, L.1    Portarena, I.2    Graziani, G.3
  • 45
    • 0036733355 scopus 로고    scopus 로고
    • The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
    • 1:CAS:528:DC%2BD38XotVSmsr8%3D 12223530 10.1124/pr.54.3.375
    • Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
    • (2002) Pharmacol Rev , vol.54 , Issue.3 , pp. 375-429
    • Virag, L.1    Szabo, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.